Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
Market Cap | 79.96B |
Revenue (ttm) | 40.10B |
Net Income (ttm) | 1.49B |
Shares Out | 157.39M |
EPS (ttm) | 10.14 |
PE Ratio | 50.12 |
Forward PE | 28.54 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 142,747 |
Average Volume | 380,476 |
Open | 513.55 |
Previous Close | 516.40 |
Day's Range | 500.00 - 518.90 |
52-Week Range | 432.60 - 1,175.90 |
Beta | n/a |
RSI | 48.42 |
Earnings Date | Jun 17, 2025 |
About NSE:AKUMS
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company. It also sells branded pharmaceutical formulations. The company was incorporated in 2004 and... [Read more]
Financial Performance
Financial StatementsNews

Akums Drugs and Pharmaceuticals shares fall over 6% following Income Tax Department search
Shares of Akums Drugs and Pharmaceuticals fell over 6% on January 22 following the company’s disclosure of an Income Tax Department search at its offices and manufacturing units. In an exchange filing...

Akums Drugs secures Rs 1,760 deal to supply oral liquid formulations in Europe
Akums Drugs and Pharmaceuticals Limited has secured a strategic agreement with a leading global pharmaceutical company for the manufacture and supply of oral liquid formulations in the European market...

Akums Drugs partners with Jagdale to revolutionize India’s Ready-to-Drink nutritional beverage market
Akums Drugs and Pharmaceuticals Ltd. has announced a strategic collaboration through its subsidiary, Maxcure Nutravedics Ltd., with Jagdale Industries Private Limited to market Ready-to-Drink (RTD) be...

Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...

Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...

Akums Drugs and Pharmaceuticals shares fall 5% following weak Q2 earnings outlook
Shares of Akums Drugs and Pharmaceuticals dropped 5% as the company reported weak Q2 earnings and projected a flat revenue outlook for the fiscal year 2024-25. The stock was trading at ₹582.10 as of 9...

Akums Drugs and Pharmaceuticals Q2 FY25 results: Revenue at ₹1,033.09 crore, down 12.5% YoY; profit at ₹66.65 crore, up 103.8% YoY
Akums Drugs and Pharmaceuticals Limited has released its financial results for Q2 FY25, showing mixed performance metrics. Key Financial Highlights: Revenue from Operations: For the quarter ended Sept...

Akums Drugs signs MoU with Zambian Ministry of Health to manufacture local medicine
Akums Drugs and Pharmaceuticals Limited (Akums) has signed a Memorandum of Understanding (MoU) with the Zambian Ministry of Health to manufacture local medicine. The MoU seeks to improve existing coll...

Akums Drugs shares surge 4% after company bags exclusive rights to develop Triple Hair products in India
Akums Drugs and Pharmaceuticals shares jumped more than 4% after the company announced that it received exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. The deal...

Akums Drugs secures exclusive rights to develop and market Triple Hair products in India
Akums Drugs and Pharmaceuticals has recently informed exchanges that the company has secured exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. This partnership ma...

McCormick Q3 Earnings Top Estimates, MKC Volumes Improve Y/Y
McCormick & Company, Incorporated (NYSE: MKC) reported solid third-quarter fiscal 2024 results, wherein the top and bottom lines beat the Zacks Consensus Estimate, and earnings increased year over ye...